Trial Profile

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bexmarilimab (Primary) ; Azacitidine; Azacitidine; Venetoclax
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms BEXMAB
Sponsors Faron Pharmaceuticals

31 May 2025 Planned End Date changed from 31 Dec 2025 to 1 Apr 2026.
31 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Apr 2026.
31 May 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com